Next Generation Sequencing of GATC Biotech AG Accredited by German DAkkS
GATC Biotech customers can expect highest quality standards for Next Generation Sequencing projects from official accreditation
Konstanz, Germany, December 3, 2012 / B3C newswire / – Being the first in Europe, the Next Generation Sequencing Laboratories of the Constance Genome and Diagnostics Centre has been accredited according to ISO 17025 from the national accreditation body for the Federal Republic of Germany (DAkks). The independent governmental institution has acknowledged the high quality standard of the sequencing service on technology platforms Illumina HiSeq and Roche GSFLX sequencing.
“As an accredited service provider we assure our customers the latest state-of-the-art standards in our methods, technologies and data quality at all times. This is especially important to our customers from the industry or diagnostics. A reliable and continuously high quality of the analysis service is of great importance to them. The accreditation allows all customers to compare the quality of service providers on the international sequencing market”, explains Dr. Marcus Benz, COO of GATC Biotech AG.
“While inspecting the laboratories, we met a very qualified and motivated team that has developed a high competency for the complex analysis. Apart from the staff and the excellent equipment, the LIMS system has to be highlighted. This in-house developed software system allows a wide monitoring of the processes and contributes especially to internal quality management”, says the DAkkS expert.
Since June 2012, the accreditation according to ISO 17025 has been official and has been confirmed by extensive audits. The Genome and Diagnostics Centre of GATC Biotech in Constance meets essential requirements for the competence of analysis and calibration laboratories such as DIN EN ISO/IEC 17025, DIN EN ISO 9001 and all further conditions. The compliance of standards is monitored by the DAkkS regularly.
About GATC Biotech
GATC Biotech is Europe’s leading service provider of DNA sequencing. For over two decades the company has offered sequencing and bioinformatics solutions for single samples, transcriptomes and regulomes, up to whole genomes. GATC has sequenced more than 5 million samples, ten thousands of bacterial, plant or other whole genomes as well as hundreds of whole human genomes for its more than 10.000 academic and industrial customers worldwide.
GATC Biotech offers true multiplatform sequencing using all leading sequencing technologies in its own labs. GATC´s acknowledged bioinformatics solutions allow high-end data analysis for its customers in pharmaceutical, diagnostic, chemical or food industries as well as in academics. As an Agilent and Illumina Certified Service Provider, GATC enables full compliance with latest state-of-the-art standards. GATC acts as a supplier for the ICGC, the International Cancer Genome Consortium.
GATC´s subsidiary LifeCodexx emphasizes the development of clinically validated molecular diagnostic tests and offers a risk-free alternative to common invasive examination methods such as amniocentesis.
Related News
-
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News CPHI North America 2024 – From the Floor
Welcome to Philly! CPHI North America once again graces the Philadelphia Convention Center, 7–9 May 2024. -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future. -
News A Day in the Life of a President and Chief Scientific Officer
We are continuing to get to know the people working day-to-day behind the pharma companies shaping the industry, the ones who keep the wheels turning and ultimately bring better healthcare to the population; we are talking to the individuals at the hea... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News LEAP-ing into the future of pharma – the CPHI Middle East Vision
On March 6, 2024, the CPHI team hosted the Future of Pharma Forum at LEAP 2024, Saudi Arabia’s premier destination for tech leaders and innovators to meet and collaborate. -
News Informa Markets International Women’s Day Panel Discussion
On March 7, 2024, the Informa Markets Amsterdam office hosted an International Women’s Day Breakfast and Panel Discussion to celebrate the women who drive the B2B events industry forward, including members of the CPHI team. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance